A dynamic transmission model for assessing the impact of pneumococcal vaccination

- 5 Tufail M Malik^{1*}, Kevin M Bakker¹, Rachel J Oidtman¹, Oluwaseun Sharomi¹, Giulio Meleleo²,
- 6 Robert B Nachbar², Elamin H Elbasha¹
- 7

4

¹Merck & Co., Inc., Rahway, NJ, USA

- ⁹ ²Wolfram Research, Inc., Champaign, IL, USA
- 10
- 11 * Corresponding author
- 12 E-mail: <u>tufail.malik@merck.com</u> (TM)
- 13

14 Abstract

Streptococcus pneumoniae (SP) is a bacterial pathogen that kills more than 300,000 children every year across the globe. Multiple vaccines exist that prevent pneumococcal disease, with each vaccine covering a variable number of the more than 100 known serotypes. Due to the high effectiveness of these vaccines, each new pneumococcal conjugate vaccine (PCV) introduction has resulted in a decrease in vaccine-type disease and a shift in the serotype distribution towards non-vaccine types in a phenomenon called serotype replacement. Here, an age-structured

21 compartmental model was created to capture the carriage transmission dynamics of SP and 22 subsequent progression to pneumococcal disease in the presence of vaccines introduced at 23 different times to different age groups. The model incorporates co-colonization and serotype 24 competition, which drives replacement of the vaccine types by the non-vaccine types. The model was calibrated to historical age- and serotype-specific invasive pneumococcal disease (IPD) data 25 from the United States. Vaccine-specific coverage and effectiveness were integrated in 26 27 accordance with the recommended timelines for each age group. Demographic parameters were derived from US-population-specific databases, while population mixing patterns were informed 28 29 by US-specific published literature on age-group based mixing matrices. The calibrated model 30 was then used to project the epidemiological impact of PCV15, a 15-valent pneumococcal vaccine, compared with the status quo vaccination with PCV13 and demonstrated the value of 31 added serotypes in PCV15. Projections revealed that PCV15 would reduce IPD incidence by 32 33 6.04% (range: 6.01% to 6.06%) over 10 years when compared to PCV13.

34

35 Introduction

Despite the widespread use of pneumococcal vaccines in the United States (US), *Streptococcus pneumoniae* (SP) caused nearly 17,400 cases of invasive pneumococcal disease (IPD) in 2021, and nearly 3,000 associated deaths [1]. Globally the number of deaths in children under 5 is approximately 300,000 [2]. Vaccines are only able to target a portion of the more than 100 circulating serotypes (STs) [3], and serotype-specific vaccine effectiveness has been observed. Only a small fraction of these cause majority of disease. Asymptomatic or symptomatic nasopharyngeal carriage (NPC) of SP in an individual, which is relatively common in young

43	children [4], may result in SP transmission to other individuals through person-to-person contact
44	via respiratory droplets. NPC can lead to multiple disease outcomes, including invasive
45	pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (NBPP), and acute otitis
46	media (AOM) [5]. IPD, which includes meningitis and bacteremic pneumonia, primarily afflicts
47	extremes of ages and those with risk factors [6]. Vaccines play a role in preventing NPC but the
48	necessary immune response is higher than what is required to prevent disease.
49	In the US a pediatric vaccination program with a 7-valent pneumococcal conjugate vaccine
50	(PCV) was introduced in 2000, and building on this composition, a 13-valent PCV was
51	introduced in 2010, followed by a 15-valent vaccine in 2022, and a 20-valent vaccine in 2023.
52	Since 1983, a 23-valent pneumococcal polysaccharide vaccine (PPSV23) had been
53	recommended for all adults 65 years or older. Vaccines targeting additional or different
54	serotypes, along with those based on other technologies, are currently in development. Since the
55	introduction of PCVs, the US has seen a dramatic reduction in IPD across all age groups in
56	vaccine-type (VT) serotypes [6]. There has also been replacement of VTs with non-vaccine types
57	(NVTs) [7]. Globally, there have been higher levels of replacement than those seen in the US,
58	sometimes leading to higher overall incidence levels than the pre-vaccine period (for example in
59	France following PCV13 introduction [8]).
60	Dynamic transmission models (DTMs) have been used extensively to describe the
61	epidemiological and biological dynamics of SP transmission in the presence or absence of
62	vaccination (Table S1 summarizes a review of published models). In this study,, a DTM was
63	developed to quantify the epidemiological impact of ST-specific and age-based vaccination
64	programs. The model is driven by carriage transmission and assigns each ST into one of 11
65	serotype classes (STCs, Table S7), which were determined based on their inclusion in different

66	pneumococcal vaccines. Additionally, the model features indirect effects such as herd immunity
67	and competition between ST classes, which determines replacement dynamics following vaccine
68	introduction. The model is flexible, so that it can be used in countries that report disease
69	incidence with different age-groups, incorporated different vaccines into their vaccine schedules
70	(e.g., PCV10), want to examine different vaccination policies, or are interested in other
71	pneumococcal diseases of interest. The model was fitted to historical (2000-2019) US IPD
72	incidence (per 100,000) data and the epidemiological impact of the continued use of PCV13
73	versus implementing PCV15 in the pediatric immunization program was assessed (at the time of
74	this study PCV20 was not yet recommended in peds in the US).

75 Methods

A model was developed that described SP carriage transmission dynamics and disease

progression in the presence of age- and serotype-specific pneumococcal vaccines. Real-world

data was used to inform parameters for vaccine effectiveness against disease, coverage rates,

duration of protection, carriage clearance rates, and a mixing within and between age groups.

80 Real-world data are lacking for PCV15 given recent introduction. Population data was used to

81 parameterize the demographic aspects of the model.

The model was calibrated to national-level IPD data in the US to estimate the probability of SP carriage acquisition per contact, competition between STCs, progression rate from carriage to disease, and vaccine effectiveness against carriage. Disease incidence data were stratified by age and grouped into STCs, based on inclusion in various vaccines (Table S7). Previous studies have employed a similar approach of grouping STs into classes and have embraced similar assumptions [9, 10, 11, 12]. With the calibrated model, epidemiological projections were made under different pediatric vaccination scenarios keeping a realistic mix of vaccination regime in
the adult population.

90 Model overview

A deterministic age-structured DTM was constructed to describe pneumococcal carriage 91 92 transmission dynamics and disease progression in the presence of age- and STC-specific 93 pneumococcal vaccines. In addition to the brief description of the model here, additional details can be found in the Supplementary Appendix. Given the lack of data to parameterize the model 94 for all serotypes and disease outcomes, it was assumed that parameter values were constant 95 across serotypes within the same STC and age group. Each STC was further categorized into 6 96 age groups (0-1, 2-4, 5-17, 18-49, 50-64, and 65+). This age grouping is chosen based on the 97 98 availability of historic IPD incidence data in the US, which was used as the calibration target. Additionally, these age groups align with vaccination policy recommendations by the Advisory 99 100 Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention 101 (CDC). For instance, pediatric vaccination historically targets children aged 0-2 years, adult 102 vaccination covers individuals aged 65 and older, and at-risk groups include those aged 19–64. 103 Future policy considerations related to adult vaccination may involve expanding age-based 104 vaccination to include adults aged 50 and older.

The model was based on a system of ordinary differential equations and distinguished
pneumococcal carriage from disease as well as their vaccine protection status, which varied by
age and vaccine type (Fig 1). For example, an unvaccinated person can be either susceptible noncolonized or colonized with up to three STCs. A fraction of infants are born into the
unvaccinated susceptible non-colonized compartment and remain there until they are vaccinated,

become colonized, or die from causes other than pneumococcal disease. Individuals acquire one or two STCs simultaneously at an age-specific and time-dependent rate (i.e., per capita force of carriage acquisition), progressing from non-colonized status to single or double colonization, from single to double or triple colonization, and from double to triple colonization. It was assumed that an individual could be colonized by up to three STCs concurrently.

Fig 1. Model flowchart. Individuals are born into the non-colonized compartments and can move throughout the system during their lifetime. Upon carriage acquisition, individuals move to the colonized (with a single ST), co-colonized with two STs, or triple-colonized compartments. Colonized individuals can clear carriage of one ST at a time. A proportion of colonized individuals will develop a pneumococcal disease. Vaccination (right arm of flowchart) reduces the chance of carriage acquisition and disease development for vaccine STCs. Vaccine can wane over time, but vaccination history is tracked. Compartments in the left arm of the flowchart are composed of vaccine-naïve and vaccine-waned individuals. Detailed model flowchart is provided in Figure S3-S5.

The rate at which uncolonized persons of a given age group acquire SP and become colonized depends on the number and type of contacts, the fraction of colonized, co-colonized, and tricolonized contacts, and the transmission probability per contact, which varies by age. The number and type of contacts are governed by a conditional probability mixing matrix, where each cell represents the probability of a person of a given age class having contact with a person in another age class (Table S4). Upon recovery, it is assumed that the person does not develop immunity and becomes completely susceptible again.

Individuals leave the unvaccinated compartments through cohort and continuous vaccination at
given rates and enter the appropriate vaccinated compartment, based on their colonization status.
They remain in the vaccinated compartments until they die, acquire SP, or their immunity wanes.
Since typical colonization is asymptomatic, individuals can be vaccinated from any of the four

126	(uncolonized	, colonized,	double colonized.	, or triple-colonized) unvaccinated comp	partments.
-----	--------------	--------------	-------------------	-----------------------	---------------------	------------

- 127 Vaccination reduces the risk of carriage acquisition and disease progression.
- 128 In the DTM, the rate of acquisition of a second or third STC is reduced due to competition from
- the currently carried STC(s). The competition parameter is determined by the relationship
- between the current and the invading STC, and can range from zero competition (i.e.,
- independence) to complete competition (i.e., exclusion), where the acquisition of the invading
- 132 STC is completely blocked by the currently carried STC(s).
- 133 Disease occurrence was modeled using a case-carrier ratio that varies by disease manifestation,
- age, STC, and vaccine-status. Progression to IPD, AOM, or NBPP were included here, while
- 135 other manifestations (such as sinusitis) or further classification (such as bacteremia) could be
- 136 included in future analyses.
- 137 In addition to the scenarios evaluated here, the model is flexible and can evaluate other vaccine
- scenarios, such as reducing the vaccination age in adults, having sequential vaccination of
- 139 different vaccines in an age group, other vaccines, or other potential policy questions.
- 140 Numerical simulations, including model calibration and projections, were implemented using
- 141 Mathematica® 14.0 (https://reference.wolfram.com/mathematica,
- 142 https://reference.wolfram.com/language/ref/NDSolve.html,
- 143 https://reference.wolfram.com/language/ref/NIntegrate.html,
- 144 https://reference.wolfram.com/language/ref/NMinimize.html).

145 Model parameters and data sources

146 Baseline values for demographic, epidemiologic, and vaccine inputs of the model were identified

147 through a targeted search of the published literature and public databases.

148 Demographic parameters

- 149 A stable equilibrium age distribution (with 2017 as the baseline year) and constant mortality
- 150 hazards for each age group were assumed, using data from the US Census Bureau website
- 151 (https://www.census.gov/). Since the implied growth rate was insignificant, constant population
- 152 was assumed over the analysis time horizon to reduce model complexity.

153 Contact mixing matrix

- 154 Mixing patterns among the population impact the transmission dynamics of an infectious
- pathogen. Mixing patterns from Prem *et al.* [13] were derived to create the 6-age group contact
- 156 matrix (see Section 3.1.3 of the Supplementary Appendix). Although transmission among adults
- 157 was allowed, it was assumed that there was no transmission of SP from adults to the pediatric
- 158 population due to limited evidence of adult-to-child transmission and vast evidence that child-to-
- child transmission drives SP dynamics [14, 15, 16].

160 Vaccine parameters

The model assumed full vaccine compliance (i.e., 3+1 doses in pediatric population) and used 161 the respective age-specific observed vaccine coverage rates (VCRs) over the historical period 162 and anticipated VCRs for projections. VCR in each vaccine-target age group is discussed in 163 Supplementary Appendix. In the model, a distinction between two types of vaccine effectiveness 164 165 (VE) was made: VEc against carriage acquisition and VEd against pneumococcal disease (VEd 166 was unique for each disease outcome of IPD, AOM, and NBPP). VEs vary by vaccine (PCV13, 167 PCV15, PCV20, and PPSV23), STC, and age group. VEds against NBPP and AOM can be seen 168 in Supplementary Table S10 and S11. VEcs were calibrated in the model.

- 169 STC- and age-specific VEds against IPD of all vaccines considered in the model were based on
- 170 clinical trials and real-world-evidence studies (Table 1). VEd of PCV13 against STC1-type (i.e.,

- 171 PCV7 STs) IPD in children was assumed to be identical to published PCV7 VEd [17]. ST-
- specific VEds for the additional PCV13 serotypes were taken from Moore *et al.* [18]. Since
- 173 VEds within an STC may vary, VEds for each STC in children were estimated as the incidence-
- 174 weighted average of individual VEds. There is no consensus regarding the VEd of PCV13 on
- serotype 3 [19]. Despite high pediatric coverage levels, real world evidence reveals that the long-
- term impact of PCV13 has had little to no effect on population-level ST3 incidence. Therefore,
- 177 VEd against ST3 in the base case was assumed to be equal to the left end point of the 95%
- 178 confidence interval from Moore *et al.* [18].

Table 1. Vaccine effectiveness against IPD by age and serotype class. (PCV20 was only considered for adult

vaccination).

		Age (years)						
	STC	0-17	18-49	50-64	65+			
	1	0.96	0.739	0.713	0.677			
	2	0.87	0.739	0.713	0.677			
CV13	3	0.303*	0.256	0.247	0.235			
Ч	4	0.883	0.739	0.713	0.677			
	5	0.86	0.739	0.713	0.677			
	6-11		0					
	1-5	Identi	Identical to PCV13 VE					
CV15	6	0.86	0.739	0.713	0.677			
Ъ	7-11	0						
	1-6	Identical to PCV15 VE						
/20	7	0						
PC	8,9	NA	0.739	0.713	0.677			
	10, 11	0						
ß	1-4, 6-	NA	0.585	0.559	0.521			
PSV2	9							
Р	5,10,11	NA	0	0	0			

IPD: Invasive Pneumococcal Disease; STC: Serotype Class; NA: Not Applicable;

PCV13: 13-valent pneumococcal conjugate vaccine; PCV15: 15-valent pneumococcal conjugate vaccine; PCV20: 20-valent pneumococcal conjugate vaccine; ST3 = serotype 3; STCs = serotype classes;

Populations in each adult age group include those at low risk for pneumococcal disease (healthy

*: left end point of 95% CI.

179

180	individuals) as well as those with increased risk due to immunocompromising conditions. The
181	VEd of PCV13 for IPD in healthy adults was based on Bonten et al. [20] and in high-risk adults
182	on Cho et al. [21], and VEd of PPSV23 was based on. These were incorporated into the age-
183	based population-level VEds based on risk distribution by age (Table S9).
184	Equivalency was assumed for the new vaccines, which is that new PCVs with additional STs (e.g
185	PCV15 and PCV20) have equivalent VEds as previous PCVs (PCV13) for shared serotypes.
186	Overall VEd of PCV13 [18] was used as VEd of PCV15 against STC6-type IPD in children.
187	PCV13 VEd in adults was not ST-specific and was extended to additional PCV15 and PCV20
188	STCs (Table 1).
189	In a scenario analysis STC-specific VEd for PCV15 was based on immune response of PCV15
190	relative to PCV13. Results of this scenario analysis are presented in the Supplementary

191 Appendix.

192 It was assumed that mean duration of protection from any PCV was 10 years, while PPSV23 was

assumed to have a mean duration of protection of 7.5 years [22].

194 Carriage clearance rates

195 Annual carriage clearance rates for a given serotype were calculated as the inverse of carriage

duration. A literature review was performed to collect data on age and serotype-specific carriage

- 197 durations. For each age-STC combination the total carriage duration across studies was divided
- by the total population across studies and normalized by age group. More details on these
- derivations are available in Section 3.2.4.1.1 of the Supplementary Appendix.

200 Model calibration

To infer the values of the age- and STC-specific probability of acquisition, age- and STC-201 specific case-carrier ratios, STC-specific competition parameters, and the STC-specific VEc for 202 the VTs, the model was calibrated to historical US IPD incidence data from 2000–2019. The 203 204 model's fit to historical data of IPD incidence was formally conducted to minimize the sum of 205 squared errors. Figure S11 of the Supplementary Appendix provides a visual validation of the 206 model's fit to the data, with the fit error shown in each plot. The calibration results, i.e., the 207 values of fitted parameters, such as invasiveness and carriage transmission probability are higher in extreme age groups, consistent with conventional wisdom and existing modeling literature. 208 209 Pneumococcal dynamics were impacted from the COVID-19 pandemic [23] through reduced 210 transmission due to non-pharmaceutical interventions and disruption of routine healthcare 211 services including vaccination. Since the model does not account for such dynamics, data after 212 2019 was not included in model calibration. Calibration methodology and detailed results are described further in the Supplementary Appendix. 213

214 Calibration target

Age-stratified STC-specific IPD incidence per 100,000 in the US from 1998-2019 was used as calibration target. The annual IPD incidence per 100,000 in the US by age group and STC was generated based on two sources: (i) the available overall (all serotypes) incidence data and (ii) the serotype distribution data. Overall incidence was obtained from the annual CDC surveillance reports [24] and the annual serotype distribution data came from Active Bacterial Core surveillance, CDC [25].

For calibration to NBPP data, pediatric NBPP incidence per 100,000 from 1998–2018 was

obtained from Hu et al. [26]. To obtain the counterpart data in adults, all-cause pneumonia

223	(ACP) incidence was acquired from Truven MarketScan Commercial Claims and Encounters
224	(January 1, 2012 to December 2020) – a healthcare claims database that contains information
225	about clinical utilization over time [27]. It was assumed that 11% of ACP had pneumococcal
226	etiology-NBPP-in US adults [28]. For pediatrics, it was assumed that ST distribution for
227	NBPP followed that of IPD. For adults, the proportion of NBPP attributable to STCs was
228	calculated using data from two recent studies [29, 30] and the STC- and age-specific data was
229	constructed (see Section 5.1 of Supplementary Appendix for additional details).
230	For AOM calibration, pediatric all-cause AOM incidence per 100,000 from 1998-2018 was
231	obtained from Hu et al. [31] of which 23.8% was pneumococcal attributable [32]. Studies with
232	ST distribution information for AOM cases [32, 33, 34] were used to construct the STC- and
233	age-specific data (see Section 5.2 in Supplementary Appendix for additional details).
234	Using the carriage prevalence profile that corresponded to calibrated IPD incidence, case-carrier
235	ratios for NBPP and AOM were then calibrated using the historical incidence of each
236	manifestation. Details on NBPP and AOM calibration, procedure, and results are provided in the
237	Supplementary Appendix.

238 Model projections

The calibrated model was then used to compare pneumococcal disease burden assuming either pediatric PCV13 or PCV15 vaccination. In adults, both PCV15 with PPSV23 or PCV20 have been recommended for use [35]. A hypothetical combination of these vaccines was constructed. In addition, given the historic practice, we assumed that healthcare providers may continue to administer PPSV23 alone. Therefore, to design an adult vaccination scenario (which would be kept same while comparing the two pediatric vaccination scenarios) it was assumed that of the vaccinated US adults 80% receive PCV20, 10% receive PCV15+PPSV23, and 10% receive

246	PPSV2	23 alone. Since adult vaccination was identical between these two scenarios, the				
247	differe	nces in model outcomes were solely caused by pediatric vaccination. A different adult				
248	vaccination scenario of 50% vaccinated adults receiving PCV20, 25% receiving					
249	PCV15+PPSV23 and 25% receiving PPSV23 (50-25-25 scenario) was examined in scenario					
250	analys	is.				
251	The tw	vo scenarios are summarized below:				
252	1.	Scenario PCV13: Children 0-2 receive PCV13 according to assumed VCR. Given				
253		assumed VCR among adults 18+, 80% receive PCV20, 10% receive PPSV23, and 10%				
254		receive PCV15+PPSV23.				
255	2.	Scenario PCV15: Children 0-2 receive PCV15 according to assumed VCR. Given				
256		assumed vaccination coverage among adults 18+, 80% receive PCV20, 10% receive				
257		PPSV23, and 10% receive PCV15+PPSV23.				

258 **Results**

259 **IPD data calibration results**

As shown in Fig 2 and 3, the model was able to capture historical trends in each of the STCs for

each age group (detailed model fit by STC/age group is given by Figure S11 in the

Supplementary Appendix). Before the introduction of a PCV in the US, PCV7 serotypes (STC1)

dominated the IPD landscape. However, after the introduction of PCV7 in 2000 and prior to the

- introduction of PCV13 in 2010, replacement occurred, with the additional PCV13 (excluding
- ST3) serotypes increasing in incidence. This replacement behavior was captured by the model
- due to the inclusion of a competition parameter. In 2010 PCV13 was introduced and all PCV13
- 267 STCs, other than ST3, declined. ST3, both in the model and data, remained relatively constant

268	across the calibration period	. Following PCV13	introduction, all	l non-vaccine S	TCs trended

- 269 upward.
- 270 Prior to PCV7, STC1 outcompeted other STs, but following PCV7 introduction, and the
- reduction in STC1 STs, STCs 4,7, &10 were able to spread due to the reduced competitive
- 272 pressure from STC1 STs
- Fig 2. Calibrated versus IPD incidence per 100,000 over time in children age groups. Dashed lines: data; Solid
 lines: model outcome.
- Fig 3. Calibrated versus IPD incidence per 100,000 over time in adult age groups. Dashed lines: data; Solid lines:
 model outcome.
- 277

IPD = invasive pneumococcal disease; PCV7 = 7-valent pneumococcal conjugate vaccine; PCV13 = 13-valent pneumococcal conjugate vaccine; PCV15 = 15-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine; ST3 = serotype 3; STCs = serotype classes; V116 = an investigational 21valent pneumococcal conjugate vaccine.

278

Years of real-world data following the introduction of new vaccines will be necessary to estimate
how new vaccine type STs, such as 22F and 33F (STC6) compete and interact with other STCs.
The model estimated age- and serotype-specific VEc, which revealed PCV7 to have a greater
impact against the 7 serotypes it targeted than PCV13 had on the additional 6 serotypes it
targeted (TableS18). The model also calculated age- and serotype-specific case-to-carrier ratios
for IPD (Table S17). Results indicated that these case-carrier ratios were highest in the youngest
and oldest age groups.

Following the calibration of the model to IPD incidence, which generated age- and STC-specific carriage acquisition rates, the model was then calibrated to estimate the age- and STC-specific case-carrier ratios for each of AOM and NBPP. The model captured changes in the serotype distribution associated with AOM after different vaccine introductions, such as the decline of 5 of the additional serotypes included in PCV13 (excluding STC3) (Figure S14). Similarly, the model replicated reductions in PCV7 STs in 2000 and STC4 (7F, 19A) in 2010 in pediatric NBPP following the introduction of PCV7 and PCV13 (Figure S13).

293 Epidemiological projections

The calibrated model was used to make projections for the two scenarios described above (Fig 294 295 4). Projections revealed that PCV15 prevented more cases of IPD, AOM, and NBPP than PCV13 across all age groups. The reduced incidence of IPD in pediatric age groups under the PCV15 296 scenario reflected the direct and indirect benefit due to the added vaccine type serotypes 22F and 297 298 33F, while the lower incidence in adult age groups was due to indirect protection (i.e., herd immunity) from the pediatric population. It was estimated that over 10 years, PCV15 would 299 reduce about 6% more cases of IPD when compared to PCV13. This includes around 13.54 more 300 cases averted in children under 2 and 4.82% more cases averted in adults over the age of 65. 301 302 With the 50-25-25 scenario (50% vaccinated adults receiving PCV20 and 25% receiving 303 PCV15+PPSV23 and 25% receiving PPSV23), PCV15 saved about 6.1% more cases of IPD than PCV13 over 10 years, including 4.9% more cases saved in adults over 65 years of age. As 304 305 expected, the number of pediatric IPD cases averted remained unchanged. 306 Fig 4. IPD incidence per 100,000 projected by the calibrated model. Top: IPD burden, children < 5; Bottom: Overall

307 IPD burden by age group. Vaccination in adults: 80% receive PCV20, 10% receive PPSV23, and 10% receive

- 308 PCV15+PPSV23. Vaccine coverage used in these projections is given by Figure S6. Reduced IPD incidence in adults
- is a result of indirect protection of pediatric PCV15 vaccination.
- 310 IPD = invasive pneumococcal disease; PCV13 = 13-valent pneumococcal conjugate vaccine; PCV15 = 15-valent
- 311 pneumococcal; STs = serotypes; VE = vaccine effectiveness
- The model estimated that after 10 years, compared to PCV13, PCV15 will also reduce the
- number of NBPP cases by 5.5% and the number of AOM cases by about 3%.

314 **Projected IPD STC distribution**

- Fig 5 shows the pre-PCV, 2019, and 10 year-projections of IPD incidence. By 2019, PCV7 and
- 316 PCV13 reduced overall IPD, however ST-distributions shifted with NVTs replacing VTs over
- this same period. The third column shows the projected shift in this distribution following 10
- years of PCV15 utilization. STs 22F and 33F (PCV15 non-PCV13) are diminished with PCV15.
- 319 There is a clear shift from vaccine-types towards NVTs (Other STs) through ST replacement.
- 320 Since PCV20 was implemented in adult age groups (18 and above) in projection period, IPD in
- the PCV20 non-PCV15 STC was reduced in adults.

Fig 5. IPD incidence (cases per 100,000) attributed to each STC grouped by vaccine in each model age group. Model calibrated STC distributions and data at the start and end of calibration period (2000 and 2019 respectively), and model projected STC distributions after 10 years of PCV15 in children.

- 322 IPD = invasive pneumococcal disease; PCV7 = 7-valent pneumococcal conjugate vaccine; PCV13 = 13-valent
- 323 pneumococcal conjugate vaccine; PCV15 = 15-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent
- 324 pneumococcal polysaccharide vaccine; ST3 = serotype 3; STCs = serotype classes

325 **Discussion**

326 An age-structured dynamic model of pneumococcal carriage transmission was developed to

- 327 evaluate the epidemiological impact of age-based vaccine policies on pneumococcal diseases.
- 328 Serotypes were divided into serotype classes (STCs) which allowed disease incidence to be
- examined by each age and STC combination.

330 The model was calibrated to the historical age-specific US IPD incidence data from 2000 to 2019

and used to project future outcomes under different vaccine strategies. The results of this

332 calibration revealed age- and serotype-specific carriage acquisition probabilities, competition

parameters between STCs, age- and serotype-specific vaccine efficacies against carriage, and

age- and serotype specific case-to-carrier ratios for invasive and non-invasive pneumococcal

disease (IPD, NBPP, and AOM). Calibrated values fell within the range of published estimates

336 where available or were aligned with calibration estimates of published models.

337

Probability of carriage acquisition per contact with a colonized individual, which is an age- and 338 STC-specific parameter, was highest in the youngest and oldest age groups due to weak immune 339 systems (i.e., immature in children [36] and deficient due to age in older adults [37]). This 340 341 implies that children in the first two age groups (aged 0-4) and individuals in the oldest age group (aged 65+) are most likely to acquire carriage upon contact with a colonized individual of 342 any age. These results are consistent with other literature (for example, see [10, 16, 38]). Case-343 to-carrier ratios for IPD followed a similar pattern, with those in the youngest and oldest age 344 345 groups most likely to develop disease from carriage acquisition [39]. Calibration estimates of case-to-carrier ratios for IPD also fall within the range of published estimates [39, 40, 41, 42]. 346

The calibrated competition parameter estimates correctly reflected the ST replacement in the US whereby NVTs increased to fill the niche that arose due to target STs declining following PCV7 and PCV13 implementation. Modeling literature highlights the role of ST competition [43] and some pneumococcal transmission models have included this feature at a higher level or in some aggregation [11, 44, 45]. However, calibrated ST competition between PCV7 STs against non-PCV7 STs, and PCV13 STs against non-PCV13 STs, to our knowledge, has not been examined at such granularity before.

Our parameter estimates of STC-specific VEc aligned with those reported in published literature [46, 47]. Like pneumococcal disease, PCVs are also less protective against ST3 acquisition [48]. This is evident from the relatively low calibrated VEc against ST3 which was also the case with other published model calibrations that reported ST-specific VEc [10]. Additionally, VEc in adults is lower than the respective STC-specific VEc in children. Since carriage acquisition is a precursor for pneumococcal disease, protection against acquisition is the first level of defense that PCVs offer; reduction in acquisition will lead to reduction in disease.

Since dynamic transmission models estimate the time-dependent dynamics of population-level 361 susceptibility along with factors that affect the transmission rate (e.g., vaccination status and 362 363 carriage acquisition in response to mixing patterns), they are well suited to provide insights into the indirect protection provided from interventions, such as including vaccination. For example, 364 a recent study [9] used dynamic transmission models to compare the epidemiologic impact of 365 switching from PCV13 to PCV15 or PCV20 in infant schedule in England. One of the research 366 367 findings of this study reveals that transitioning from PCV13 to PCV15 in the pediatric 368 vaccination program in the UK resulted in the unintended consequence of increased incidence of 369 IPD. However, the implementation of our model to the US data using a different structure and

370 assumptions demonstrated a decline in IPD cases if a transition from PCV13 to PCV15 were to 371 occur. Indirect protection of pediatric vaccination on adults which has been observed in 372 programs where pneumococcal vaccines have been implemented in pediatric programs [49], can 373 be analyzed in detail using this model. Here, identical vaccination strategies in adults were kept and the two different vaccination programs in children, PCV13 versus PCV15, were compared. 374 375 Due to indirect protection (i.e., herd immunity), the implementation of PCV15 in pediatrics led 376 to additional reductions in adult disease attributed to 22F and 33F. 377 The model does have some limitations. First, because of lack of data to estimate some parameters 378 such as STC-specific probability of SP acquisition we inferred the values of some of these 379 parameters by calibrating the model outcomes to historical data. Second, certain serotypes, such as serotype 3, have evolved under pressure from vaccination [50, 51] but the model does not 380 account for such evolution, assuming the same properties of STCs throughout the calibration and 381 projection horizons. Since there is very little evidence of meaningful transmission from adults to 382 children, our model assumes no transmission from adults to children [14] so there is no indirect 383 384 effect of vaccinating adults on children. Though this conservative assumption helps prevent any 385 overstatement of the potential value for adult vaccines, it may limit any implications on model 386 projections arising from possible adults-to-children transmission. It is also worth highlighting

that including several STs into a single STC entails strong assumption that STs in the same STChave identical properties.

The flexibility and accuracy of the model demonstrates promise for future adaptions in other settings, where local pneumococcal epidemiology may vary, such as different age-reporting, vaccine history, vaccine dosing, vaccine efficacies, different STs of interest, or different policy questions. The model implemented here focused on epidemiological outcomes, but in future

- 393 work the model could additionally be used to evaluate the cost-effectiveness of different
- vaccines or vaccination strategies. Understanding that certain viral pathogens, such as respiratory
- syncytial virus, influenza, and human metapneumovirus may facilitate IPD [52, 53, 54, 55],
- historical data from these pathogens can also be included into the model to capture some of the
- unexplained inter-annual variation in IPD incidence.
- 398 **Conflicts of Interest:** TM, KB, RO, OS, and EE are full-time employees of Merck Sharp &
- 399 Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may hold stock or stock
- 400 options in Merck & Co., Inc., Rahway, NJ, USA. GM and RN are consultants whose institution
- 401 (Wolfram Research, Inc., Champaign IL, USA) is paid by Merck Sharp & Dohme. RN may hold
- 402 stock or stock options in Merck & Co., Inc., Rahway, NJ, USA.
- 403 **References**
- 404
- [1] "Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae," Centers for Disease Control and Prevention, 1998-2021. [Online]. Available: https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2021.pdf. [Accessed 17 April 2024].
- [2] Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al., "Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15," *Lancet Glob Health*, vol. 6, pp. e744e757, 2018.
- [3] Hausdorff W, Feikin D and Klugman K, "Epidemiological differences among pneumococcal serotypes," *Lancet Infect Dis*, vol. 5, pp. 83-93, 2005.
- [4] Jagne I, von Mollendorf C, Wee-Hee A, Ortika B, Satzke C and Russell F, "A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age," *Vaccine*, vol. 41, pp. 3028-37, 2023.
- [5] Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien K, et al., "The fundamental link between pneumococcal carriage and disease," *Expert Rev Vaccines*, vol. 11, pp. 841-55, 2012.

- [6] Gierke R, Wodi AP and Kobayashi M, "Epidemiology and Prevention of Vaccine-Preventable Diseases," Centers for Disease Control and Prevention, 18 August 2021. [Online]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html. [Accessed 17 April 2024].
- [7] Weinberger DM, Malley R and Lispitch M, "Serotype replacement in disease after pneumococcal vaccination," *Lancet*, vol. 6736, no. 10, pp. 1962-73, 2011.
- [8] Ouldali N, Varon E, Levy C, Angoulvant F, Georges S, Ploy M-C, et al., "Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study," *Lancet Infect Dis*, vol. 21, pp. 137-47, 2021.
- [9] Choi YH, Bertran M, Litt DJ, Ladhani SN and Miller E, "Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study," *Lancet Public Health*, vol. 9, pp. e654-e663, 2024.
- [10] Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, et al., "Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK," *Epidemiol Infect*, vol. 146, no. 14, pp. 1797-806, 2018.
- [11] Melegaro A, Choi Y, George R, Edmunds W, Miller E and Gay N, "Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease," *BMC Infect Dis*, vol. 90, p. 10, 2010.
- [12] Bottomley C, Roca A, Hill P, Greenwood B and Isham V, "A mathematical model of serotype replacement in pneumococcal carriage following vaccination.," J R Soc Interface, vol. 10, no. 89, p. 20130786., 2013.
- [13] Prem K, Cook A and Jit M, "Projecting social contact matrices in 152 countries using contact surveys and demographic data," *PLoS Comput Biol,* vol. 13, 2017.
- [14] Althouse B, Hammitt L, Grant L, Wagner B, Reid R, Larzelere-Hinton F, et al., "Identifying transmission routes of Streptococcus pneumoniae and sources of acquisitions in high transmission communities," *Epidemiol Infect*, vol. 145, no. 13, pp. 2750-8, 2017.
- [15] Steurer LM, Hetzmannseder M, Willinger B, Starzengruber P, Mikula-Pratschke C, Kormann-Klement A, et al., "Streptococcus pneumoniae colonization in health care professionals at a tertiary university pediatric hospital," *Clin Microbiol Infect Dis*, vol. 41, pp. 971-976, 2022.
- [16] Mosser JF, Grant LR, Millar EV, Weatherholtz RC, Jackson DM, Beall B, et al., "Nasopharyngeal carriage and transmission of Streptococcus pneumoniae in American Indian households after a decade of pneumococcal conjugate vaccine use," *PLoS One*, vol. 9, 2014.
- [17] Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al., "Effectiveness of sevenvalent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-

control study," Lancet, vol. 368, no. 9546, pp. 1495-502, 2006.

- [18] Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, et al., "Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study," *Lancet Respir Med*, vol. 4, no. 5, pp. 399-406, 2016.
- [19] Pilishvili T, "13-valent pneumococcal conugate vaccine (PCV13) effects on disease caused by serotype 3 (Advisory Committee on Immunization Practices)," 28 February 2019. [Online]. Available: https://stacks.cdc.gov/view/cdc/78091.
- [20] Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al., "Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults," *N Engl J Med*, vol. 372, no. 12, pp. 1114-25, 2015.
- [21] Cho BH, Stoecker C, Lin-Gelles R and Moore MR, "Cost-effectiveness of administering 13-valent pneumococcalconjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions," *Vaccine*, vol. 31, pp. 6011-6021, 2013.
- [22] Treskova M, Scholz SM and Kuhlmann A, "Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions," *PharmacoEconomics*, vol. 37, pp. 1093-1127, 2019.
- [23] Dagan R, Danino D and Weinberger D, "The Pneumococcus-Respiratory Virus Connection-Unexpected Lessons From the COVID-19 Pandemic," *JAMA Netw Open*, vol. 5, 2022.
- [24] "Active Bacterial Core surveillance; Surveillance Reports," Centers for Disease Control and Prevention, 13 09 2024. [Online]. Available: https://www.cdc.gov/abcs/reports/index.html. [Accessed 10 10 2024].
- [25] "1998-2022 Serotype Data for Invasive Pneumococcal Disease Cases by Age Group from Active Bacterial Core surveillance," Active Bacterial Core Surveillance, 22 07 2024. [Online]. Available: https://data.cdc.gov/Public-Health-Surveillance/1998-2022-Serotype-Data-for-Invasive-Pneumococcal-/qvzb-qs6p/about_data. [Accessed 19 09 2024].
- [26] Hu T, Sarpong EM, Song Y, Done N, Liu Q, Lemus-Wirtz E, et al., "Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis," *Pneumonia (Nathan)*, vol. 15, no. 1, 2023.
- [27] Butler AM, Nickel KB, Overman RA and Brookhart MA, "IBM MarketScan Research Databases," in Sturkenboom, M., Schink, T. (eds) Databases for Pharmacoepidemiological Research. Springer Series on Epidemiology and Public Health ((SSEH)), Springer, 2021, pp. 243-251.
- [28] Choi MJ, Song JY, Cheong HJ, Jeon JH, Kang SH, Jung EJ, et al., "Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes," *J Infect Chemother*, vol. 21, no. 9,

pp. 672-9, 2015.

- [29] Isturiz R, Grant L and Gray S, et al., "Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults," *Clin Infect Dis*, vol. 73, no. 7, pp. 1216-22, 2021.
- [30] Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, et al., "Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia," *Vaccine*, vol. 37, no. 25, pp. 3352-61, 2019.
- [31] Hu T, Done N, Petigara T, Mohanty S, Song Y, Liu Q, et al., "Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018," *BMC Infec Dis*, vol. 22, no. 1, 2022.
- [32] Kaur R, Fuji N and Pichichero ME, et al., "Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019," *Eur J Clin Microbiol Infect Dis*, vol. 41, no. 1, pp. 37-44, 2022.
- [33] Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R, et al., "Pneumococcal serotypes from acute otitis media in rural Kentucky," *Pediatr Infect Dis J*, vol. 21, no. 9, pp. 859-65, 2002.
- [34] Casey JR, Adlowitz DG and Pichichero ME, et al., "New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine," *Pediatr Infect Dis J*, vol. 29, no. 4, pp. 304-9, 2010.
- [35] Kobayashi M, Farrar JL, Gierke R, Leidner AJ, Campos-Outcalt D, Morgan RL, et al., "Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022," MMWR, vol. 71, pp. 1174-81, 2022.
- [36] Lambert L and Culley F, et al., "Innate Immunity to Respiratory Infection in Early Life," *Front Immunol*, vol. 8, 2017.
- [37] Krone C, van-de-Groep K, Trzcinski K, Sanders E and Bogaert D, et al., "Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions," *Lancet Respir Med*, vol. 2, pp. 141-53, 2014.
- [38] Melegaro A, Gay N and Medley G, "Estimating the transmission parameters of pneumococcal carriage in households," *Epidemiol Infect*, vol. 132, pp. 433-41, 2004.
- [39] Choi Y, Jit M, Flasche S, Gay N and Miller E, "Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales," *PLoS One.*, vol. 7, no. 7, p. e39927, 2012.
- [40] Southern J, Andrews N, Sandu P, Sheppard CL, Waight PA, Fry NK, et al., "Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal

conjugate vaccine in England," PLoS One, vol. 13, 2018.

- [41] Yildirim I, Little B, Finkelstein J, Lee G, Hanage W, Shea K, et al., "Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts' children to relatively low invasiveness," *Vaccine*, vol. 35, pp. 4002-9, 2017.
- [42] Lochen A and Anderson R, "Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations," *Clin Microbiol Infect*, vol. 26, no. 1, pp. 60-70, 2020.
- [43] Lipsitch M, "Vaccination against colonizing bacteria with multiple serotypes," *Proc Natl Acad Sci U.S.A.*, vol. 94, no. 12, pp. 6571-6, 1997.
- [44] Masala G, Lipsitch M, Bottomley C and Flasche S, "Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination," *J R Soc Interface*, vol. 14, no. 136, 2017.
- [45] De-Cao E, Melegaro A, Klok R and Postma M, "Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling," *PLoS One*, vol. 9, no. 4, p. e89415., 2014.
- [46] Gjini E, "Geographic variation in pneumococcal vaccine efficacy estimated from dynamic modeling of epidemiological data post-PCV7," *Sci Rep*, vol. 7, no. 1, p. 3049, 2017.
- [47] Rinta-Kokko H, Dagan R, Givon-Lavi N and Auranen K, "Estimation of vaccine efficacy against acquisition of pneumococcal carriage," *Vaccine*, vol. 27, no. 29, pp. 3831-7, 2009.
- [48] Lapidot R, Shea K, Yildirim I, Cabral H, Pelton S and The Massachusetts Department of Public Health, "Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts," *Pathogens*, vol. 9, 2020.
- [49] Miller E, Andrews N, Waight P, Slack M and George R, "Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study," *Lancet Infect Dis,* vol. 11, pp. 760-8, 2011.
- [50] Groves N, Sheppard CL, Litt D, Rose S, Njoku ASN, Rodrigues S, et al., "Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader," *Genes (Basel)*, vol. 10, 2019.
- [51] Azarian T, Mitchell PK, Georgieva M, Thompson CM, Ghouila A, Pollard AJ, et al., "Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci," *PLoS Pathog*, vol. 14, 2018.
- [52] Ben-Shimol S, Greenberg D, Hazan G, Shemer-Avni Y, Givon-Lavi N and Dagan R, "Seasonality of both bacteremic and nonbacteremic pneumonia coincides with viral lower respiratory tract infections in early childhood, in contrast to nonpneumonia invasive pneumococcal disease, in the pre-pneumococcal conjugate vaccine era," *Clin Infect Dis*, vol. 60, no. 9, pp. 1984-7, 2015.

- [53] Weinberger DM, Grant LR, Steiner CA, Weatherholtz R, Santosham M, Viboud C, et al., "Seasonal Drivers of Pneumococcal Disease Incidence: Impact of Bacterial Carriage and Viral Activity," CID, vol. 584, 2014.
- [54] Weinberger DM, Harboe ZB, Viboud C, Krause TG, Miller M, Mølbak K, et al., "Serotype-specific effect of influenza on adult invasive pneumococcal pneumonia," J Infect Dis, vol. 208, no. 8, pp. 1274-80, 2013.
- [55] Stensballe LG, Hjuler T, Andersen A, Kaltoft M, Ravn H, Aaby P, et al., "Hospitalization for respiratory syncytial virus infection and invasive pneumococcal disease in Danish children aged <2 years: a population-based cohort study," *Clin Infect Dis*, vol. 46, no. 8, pp. 1165-71, 2008.

405

406

407 **Supporting information**

408 S1 Text. Supplementary Appendix

Proprietary









